Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UDUET
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Telisotuzumab-ADC
|
|||||
| Synonyms |
Telisotuzumab-ADC
Click to Show/Hide
|
|||||
| Organization |
XADCERA BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
|
|||||
| Drug Status |
Investigative
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
Trophoblast glycoprotein (TPBG)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
| Standard Type | Value | Units | Animal Model (No. of PDX) |
|---|---|---|---|
| Tumor Growth lnhibition value (TGl) |
11.3
|
%
|
TPBG Patient-derived Xenograft Model
|
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal inhibitory Concentration (lC50) |
61.9
|
ug/ml
|
CVCL_1544
|
Pleural epithelioid mesothelioma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
11.30%
|
|||
| Method Description |
The patient-derived tumor firagments (2mmx2mmx2mm) were engraftedin the right flank of B-NDG mice (Biocytogen Pharmaceuticals (Beijing) Co., Ltd., Cat#: B-CM-002). Treatment with 3mg/kg (QWƦ,i.v.) ADC after tumor volume about 200-300mm3. Determined tumor volume after the experiment, measured at day 28.
|
||||
| In Vivo Model | TPBG Patient-derived Xenograft Model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
61.9 ug/ml
|
|||
| Method Description |
Series diluted ADCs (maximum concentration: 20 ug/mL, 3-fold dilutions, 10 gradients)were used to treat human lung squamous carcinoma NCI-H226 5000cells cultured in a cellculture plate, and the killing activity was detected after 72 hours of incubation in IncuCyte (Sartorius AG, IncuCytee S3).
|
||||
| In Vitro Model | Pleural epithelioid mesothelioma | NCI-H226 cells | CVCL_1544 | ||